Randolph Co Inc buys $17,627,730 stake in Quest Diagnostics Inc (DGX)

Quest Diagnostics Inc (DGX) : Randolph Co Inc scooped up 29,725 additional shares in Quest Diagnostics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 19, 2016. The investment management firm now holds a total of 234,100 shares of Quest Diagnostics Inc which is valued at $17,627,730.Quest Diagnostics Inc makes up approximately 3.89% of Randolph Co Inc’s portfolio.

Quest Diagnostics Inc opened for trading at $75.14 and hit $75.5 on the upside on Friday, eventually ending the session at $75.3, with a gain of 0.40% or 0.3 points. The heightened volatility saw the trading volume jump to 10,08,599 shares. Company has a market cap of $10,750 M.

Other Hedge Funds, Including , Gateway Investment Advisers reduced its stake in DGX by selling 3,717 shares or 1.56% in the most recent quarter. The Hedge Fund company now holds 235,024 shares of DGX which is valued at $17,697,307. Quest Diagnostics Inc makes up approx 0.15% of Gateway Investment Advisers’s portfolio.Gemmer Asset Management reduced its stake in DGX by selling 4 shares or 4.35% in the most recent quarter. The Hedge Fund company now holds 88 shares of DGX which is valued at $6,552. Santa Fe Partners added DGX to its portfolio by purchasing 42,832 company shares during the most recent quarter which is valued at $3,188,842. Quest Diagnostics Inc makes up approx 0.52% of Santa Fe Partners’s portfolio.Creative Planning boosted its stake in DGX in the latest quarter, The investment management firm added 173 additional shares and now holds a total of 1,738 shares of Quest Diagnostics Inc which is valued at $126,266.

On the company’s financial health, Quest Diagnostics Inc reported $1.12 EPS for the quarter, based on the information available during the earnings call on Apr 21, 2016. Analyst had a consensus estimate of $1.12. The company had revenue of $1863.00 million for the quarter, compared to analysts expectations of $1823.36 million. The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.05 EPS.

Many Wall Street Analysts have commented on Quest Diagnostics Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 22, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 76 from a previous price target of $70 .Company shares were Reiterated by Barclays on Apr 22, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $72 .Company shares were Reiterated by Mizuho on Apr 21, 2016 to “Buy”, Firm has raised the Price Target to $ 84 from a previous price target of $75 .

Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Company’s other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.

Leave a Reply

Quest Diagnostics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Quest Diagnostics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.